Élisabeth Quoix

14.1k total citations · 3 hit papers
256 papers, 8.3k citations indexed

About

Élisabeth Quoix is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Epidemiology. According to data from OpenAlex, Élisabeth Quoix has authored 256 papers receiving a total of 8.3k indexed citations (citations by other indexed papers that have themselves been cited), including 162 papers in Pulmonary and Respiratory Medicine, 137 papers in Oncology and 52 papers in Epidemiology. Recurrent topics in Élisabeth Quoix's work include Lung Cancer Treatments and Mutations (130 papers), Lung Cancer Research Studies (83 papers) and Lung Cancer Diagnosis and Treatment (79 papers). Élisabeth Quoix is often cited by papers focused on Lung Cancer Treatments and Mutations (130 papers), Lung Cancer Research Studies (83 papers) and Lung Cancer Diagnosis and Treatment (79 papers). Élisabeth Quoix collaborates with scholars based in France, United States and Netherlands. Élisabeth Quoix's co-authors include Thierry Le Chevalier, Anne Charloux, R. Arriagada, Fabrice Barlési, Julien Mazières, B. Milleron, Virginie Westeel, A. Laplanche, Jean‐Yves Douillard and G. Pauli and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Élisabeth Quoix

240 papers receiving 8.0k citations

Hit Papers

Radiotherapy Alone Versus... 1991 2026 2002 2014 1991 2016 2016 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Radiotherapy Alone Versus Combined Chemotherapy and Radiotherapy in Nonresectable Non-Small-Cell Lung Cancer: First Analysis of a Randomized Trial in 353 Patients
    1991 623 citations Élisabeth Quoix et al. profile →
  2. Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial
    2016 612 citations Benjamin Besse, Pierre-Jean Souquet et al. profile →
  3. Dabrafenib in patients with BRAFV600E-positive advanced non-small-cell lung cancer: a single-arm, multicentre, open-label, phase 2 trial
    2016 334 citations Julien Mazières, Élisabeth Quoix et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Élisabeth Quoix France 43 5.4k 5.1k 2.0k 1.3k 812 256 8.3k
Philip Bonomi United States 42 4.4k 0.8× 4.9k 1.0× 2.1k 1.0× 652 0.5× 978 1.2× 241 8.0k
Marcello Tiseo Italy 49 5.4k 1.0× 5.1k 1.0× 2.8k 1.4× 909 0.7× 1.4k 1.8× 373 8.5k
Alan B. Sandler United States 44 3.7k 0.7× 4.5k 0.9× 2.4k 1.2× 554 0.4× 1.0k 1.3× 109 7.5k
Suzanne E. Dahlberg United States 52 4.8k 0.9× 4.7k 0.9× 2.7k 1.3× 696 0.5× 1.7k 2.1× 150 9.3k
Gregory P. Kalemkerian United States 45 3.9k 0.7× 3.9k 0.8× 2.3k 1.1× 1.4k 1.1× 1.2k 1.5× 179 7.8k
Frank V. Fossella United States 47 9.1k 1.7× 8.6k 1.7× 2.5k 1.2× 672 0.5× 1.1k 1.3× 197 12.8k
George R. Simon United States 47 3.8k 0.7× 3.1k 0.6× 2.5k 1.2× 730 0.6× 972 1.2× 234 7.6k
Wilfried Eberhardt Germany 39 5.3k 1.0× 4.2k 0.8× 1.7k 0.8× 429 0.3× 892 1.1× 239 7.6k
Hiroshi Nokihara Japan 40 3.3k 0.6× 3.9k 0.8× 1.7k 0.8× 656 0.5× 935 1.2× 237 5.9k
Mark R. Green United States 37 7.3k 1.3× 5.0k 1.0× 979 0.5× 1.1k 0.8× 565 0.7× 131 9.8k

Countries citing papers authored by Élisabeth Quoix

Since Specialization
Citations

This map shows the geographic impact of Élisabeth Quoix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Élisabeth Quoix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Élisabeth Quoix more than expected).

Fields of papers citing papers by Élisabeth Quoix

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Élisabeth Quoix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Élisabeth Quoix. The network helps show where Élisabeth Quoix may publish in the future.

Co-authorship network of co-authors of Élisabeth Quoix

This figure shows the co-authorship network connecting the top 25 collaborators of Élisabeth Quoix. A scholar is included among the top collaborators of Élisabeth Quoix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Élisabeth Quoix. Élisabeth Quoix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Leduc, Charlotte, Nathalie Prim, B. Mennecier, et al.. (2016). Diagnosis of Jejunal Metastases from Lung Cancer Using Capsule Endoscopy. Case Reports in Oncology. 9(3). 526–529. 5 indexed citations
2.
3.
Leduc, Charlotte & Élisabeth Quoix. (2016). Is there really a role for the comprehensive geriatric assessment in metastatic non-small cell lung cancer?. Translational Cancer Research. 5(1). 1 indexed citations
4.
Couraud, S., D. Debieuvre, L. Moreau, et al.. (2015). No impact of passive smoke on the somatic profile of lung cancers in never-smokers. European Respiratory Journal. 45(5). 1415–1425. 19 indexed citations
5.
Moro‐Sibilot, Denis, Clarisse Audigier-Valette, P. Merle, et al.. (2015). Non-small cell lung cancer recurrence following surgery and perioperative chemotherapy: Comparison of two chemotherapy regimens (IFCT-0702: A randomized phase 3 final results study). Lung Cancer. 89(2). 139–145. 8 indexed citations
6.
Fraipont, Florence de, Guénaëlle Levallet, Christian Créveuil, et al.. (2012). An Apoptosis Methylation Prognostic Signature for Early Lung Cancer in the IFCT-0002 Trial. Clinical Cancer Research. 18(10). 2976–2986. 46 indexed citations
7.
Levallet, Guénaëlle, Emmanuel Bergot, Martine Antoine, et al.. (2012). High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway. Molecular Cancer Therapeutics. 11(5). 1203–1213. 74 indexed citations
8.
Borget, Isabelle, Jacques Cadranel, Jean‐Pierre Pignon, et al.. (2011). Cost-effectiveness of three strategies for second-line erlotinib initiation in nonsmall-cell lung cancer: the ERMETIC study part 3. European Respiratory Journal. 39(1). 172–179. 27 indexed citations
9.
Quoix, Élisabeth, et al.. (2008). Sarcoïdose des voies aériennes supérieures : à propos de 4 observations. Revue des Maladies Respiratoires. 17(4). 863–866. 1 indexed citations
10.
Pujol, Jean Louis, Radj Gervais, Marie‐Laure Tanguy, et al.. (2007). Phase III Double-Blind, Placebo-Controlled Study of Thalidomide in Extensive-Disease Small-Cell Lung Cancer After Response to Chemotherapy: An Intergroup Study FNCLCC cleo04–IFCT 00-01. Journal of Clinical Oncology. 25(25). 3945–3951. 97 indexed citations
11.
Eckardt, John R., Joachim von Pawel, Jean-Louis Pujol, et al.. (2007). Phase III Study of Oral Compared With Intravenous Topotecan As Second-Line Therapy in Small-Cell Lung Cancer. Journal of Clinical Oncology. 25(15). 2086–2092. 274 indexed citations
12.
13.
Hédelin, Guy, et al.. (2005). Non-small-cell lung cancer in a French department, (1982–1997): management and outcome. British Journal of Cancer. 92(3). 459–466. 27 indexed citations
14.
15.
Quoix, Élisabeth. (2004). Particularités du cancer bronchique chez la femme.. Revue de Pneumologie Clinique. 60. 3 indexed citations
16.
Quoix, Élisabeth. (2004). [Methodology for the assessment of new targeted treatments in clinical trials. Future perspectives].. PubMed. 60(5 Pt 2). 3S72–8.
17.
Sculier, Jean‐Paul & Élisabeth Quoix. (2003). Complications aiguës des cancers broncho-pulmonaires primitifs.. Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles). 53(7). 752–755. 1 indexed citations
18.
Mennecier, B., Marie-Paule Lebitasy, L. Moreau, et al.. (2003). Women and small cell lung cancer: social characteristics, medical history, management and survival. Lung Cancer. 42(2). 141–152. 18 indexed citations
19.
Quoix, Élisabeth, et al.. (1995). Traitement antifongique curatif de l'aspergillose pulmonaire invasive.. Revue de Pneumologie Clinique. 51(4). 1 indexed citations
20.
Levêque, Dominique, F. Jehl, Élisabeth Quoix, & H. Monteil. (1993). Pharmacokinetic profile of vinorelbine, a new semi-synthetic vinca alkaloid, determined by high-performance liquid chromatography. Xenobiotica. 23(11). 1325–1333. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philip Bonomi Breakdown of academic impact, for papers by Marcello Tiseo Breakdown of academic impact, for papers by Alan B. Sandler Breakdown of academic impact, for papers by Suzanne E. Dahlberg Breakdown of academic impact, for papers by Gregory P. Kalemkerian Breakdown of academic impact, for papers by Frank V. Fossella Breakdown of academic impact, for papers by George R. Simon Breakdown of academic impact, for papers by Wilfried Eberhardt Breakdown of academic impact, for papers by Hiroshi Nokihara Breakdown of academic impact, for papers by Mark R. Green
Rankless by CCL
2026